Europe In Vivo Cro Market Size & Outlook, 2024-2030
Europe in vivo cro market, 2018-2030 (US$M)
Related Markets
Europe in vivo cro market highlights
- The Europe in vivo cro market generated a revenue of USD 1,615.9 million in 2023.
- The market is expected to grow at a CAGR of 7.8% from 2024 to 2030.
- In terms of segment, small molecule was the largest revenue generating modality type in 2023.
- Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.
- Country-wise, Spain is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 1,615.9 million |
| Market revenue in 2030 | USD 2,737.2 million |
| Growth rate | 7.8% (CAGR from 2023 to 2030) |
| Largest segment | Small molecule |
| Fastest growing segment | Large Molecule |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Other key industry trends
- In terms of revenue, Europe region accounted for 35.0% of the global in vivo cro market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 823.6 million by 2030.
Small molecule was the largest segment with a revenue share of 63.61% in 2024. Horizon Databook has segmented the Europe in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
In 2022, Europe accounted for the second-largest market share. Growth in the region can be attributed to the increase in big pharmaceutical outsourcing expenditure, focus on rare diseases with unmet needs, patent expiry of biologicals, and the arrival of new biosimilars. In Europe, the field of drug discovery is undergoing rapid transformation.
Advancements in combinatorial chemistry, genomics, high throughput screening, and proteomics have revolutionized the process of moving drugs from the discovery phase to the development phase. This is primarily due to the substantial increase in available data, facilitated by the advancements in database management systems.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
In Vivo CRO Market Scope
In Vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe in vivo cro market size, by country, 2018-2030 (US$M)
Europe In Vivo CRO Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
